Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
Clinical trial NCT04626908 · UNKNOWN
Trial details
- NCT number
- NCT04626908
- Sponsor
- He Huang
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-20
- Primary completion
- 2022-06-30
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.